Design, potential and limitations of conjugation‐based antibacterial strategies

Abstract

Abstract Over the past few decades, the global spread of antimicrobial resistance has underscored the urgent need to develop innovative non‐antibiotic antibacterial strategies and to reduce antibiotic use worldwide. In response to this challenge, several methods have been developed that rely on gene transfer by conjugation to deliver toxic compounds or CRISPR systems specifically designed to kill or resensitize target bacterial strains to antibiotics. This review explores the design, potential, and limitations of these conjugation‐based antibacterial strategies, focusing on the recent advances in the delivery of CRISPR systems as antibacterial effectors.